Cellectar Biosciences

Cellectar Biosciences(CLRB)

FLORHAM PARK, NJ
Biotechnology

Focus: Small Molecules

Cellectar Biosciences is a life sciences company focused on Small Molecules.

OncologyInfectious DiseasesUnknown
Funding Stage
PUBLIC
Open Jobs
1

Pipeline & Clinical Trials

Phase 1
Clinical Trials (1)
NCT04105543CLR 131 Combined With Radiation for Head and Neck Cancer
Phase 1
I-131-CLR1404
Multiple Myeloma
Phase 1
Clinical Trials (1)
NCT02278315Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1
Phase 1
Clinical Trials (1)
NCT03478462Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma
Phase 1
Phase 1
Clinical Trials (1)
NCT00372983Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy
Phase 1
I-131-CLR1404
Cancer
Phase 1
Clinical Trials (1)
NCT01495663Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned
Phase 1
Phase 1
Clinical Trials (1)
NCT05610891Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
Phase 1
Clinical Trials (1)
NCT00582283NM404 as an Imaging Agent in Patients With NSCLC
Phase 1
I-131-CLR1404
Solid Tumors
Phase 1
Clinical Trials (1)
NCT00925275Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors
Phase 1
Iopofosine I 131
Breast Cancer
Phase 1
Clinical Trials (1)
NCT07311993Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Phase 1
I-131-CLR1404 Injection
Glioma
Phase 2
Clinical Trials (1)
NCT01778088Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma
Phase 2
Phase 2
Clinical Trials (1)
NCT01058512A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
Phase 2
Iopofosine I 131 single dose
Waldenstrom Macroglobulinemia
Phase 2
Clinical Trials (1)
NCT02952508Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia
Phase 2
NOV-002
Leukemia
Phase 2
Clinical Trials (1)
NCT00960726NOV-002 in Myelodysplastic Syndrome (MDS)
Phase 2
Phase 2
Clinical Trials (1)
NCT00345540Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer
Phase 2
I-124-CLR1404
Glioblastoma
Phase 2
Clinical Trials (1)
NCT01898273Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Phase 2
Clinical Trials (1)
NCT00347412Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3

Open Jobs (1)

Interview Prep Quick Facts
Portfolio: 17 clinical trials
SEC Filings: 2 available
Open Roles: 1 active job

Financials (FY2025)

R&D Spend
$26M4%
Net Income
-$45M
Cash
$23M